I
Immuneering Corp
NASDAQ:IMRX
Immuneering Corp
NASDAQ:IMRX
Price:
1.44 USD
3.6%
Market Closed
Updated:
May 29, 2024
Immuneering Corp
Total Liabilities
|
Immuneering Corp
Total Liabilities Peer Comparison
Comparables:
ABBV
GILD
AMGN
VRTX
REGN
Competitive Total Liabilities Analysis
Latest Figures & CAGR of Competitors
Latest Figures & CAGR of Competitors
| Company | Total Liabilities | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
|---|---|---|---|---|---|
|
I
|
Immuneering Corp
NASDAQ:IMRX
|
Total Liabilities
$12m
|
CAGR 3-Years
62%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Abbvie Inc
NYSE:ABBV
|
Total Liabilities
$140.9B
|
CAGR 3-Years
1%
|
CAGR 5-Years
17%
|
CAGR 10-Years
19%
|
|
|
Gilead Sciences Inc
NASDAQ:GILD
|
Total Liabilities
$38.8B
|
CAGR 3-Years
-7%
|
CAGR 5-Years
-1%
|
CAGR 10-Years
10%
|
|
|
Amgen Inc
NASDAQ:AMGN
|
Total Liabilities
$88B
|
CAGR 3-Years
18%
|
CAGR 5-Years
11%
|
CAGR 10-Years
7%
|
|
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
Total Liabilities
$5.4B
|
CAGR 3-Years
20%
|
CAGR 5-Years
24%
|
CAGR 10-Years
19%
|
|
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
Total Liabilities
$7.4B
|
CAGR 3-Years
8%
|
CAGR 5-Years
17%
|
CAGR 10-Years
22%
|
See Also
What is Immuneering Corp's Total Liabilities?
Total Liabilities
12m
USD
12m
USD
Based on the financial report for Dec 31, 2023, Immuneering Corp's Total Liabilities amounts to 12m USD.
What is Immuneering Corp's Total Liabilities growth rate?
Total Liabilities CAGR 3Y
62%
62%
Over the last year, the Total Liabilities growth was -4%. The average annual Total Liabilities growth rates for Immuneering Corp have been 62% over the past three years .
You don't have any saved screeners yet
